Quantum BioPharma Ltd. (QNTM) Income Statement
QNTM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsQNTM revenue and net income
QNTM profit margins
QNTM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
QNTM quarterly EPS vs estimates
Quantum BioPharma beat the analyst EPS estimate in 2 of the last 6 quarters. Next report: November 6, 2026.
QNTM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $20,630 | $0 | $0 |
| Cost of revenue | $555,334 | $490,571 | — | — | — | — | $182,612 | $0 | — | — |
| Gross profit | −$555,334 | −$490,571 | — | — | — | — | −$182,612 | $20,630 | — | — |
| Research & development | $2.8M | $6.1M | $3.9M | $6.9M | $6.3M | $7.8M | — | — | — | — |
| Sales, general & admin | $12.0M | $9.3M | $13.2M | $16.0M | $23.4M | $18.1M | $17.5M | $2.8M | $29,628 | $32,800 |
| Total operating expenses | $15.3M | $16.1M | $23.8M | $27.4M | $33.7M | $30.7M | $18.6M | $2.8M | $177,984 | $32,800 |
| Operating income | −$15.3M | −$16.1M | −$23.8M | −$27.4M | −$33.7M | −$30.7M | — | −$2.8M | — | — |
| Interest income | $236,084 | $572,891 | $786,363 | $367,735 | $1,292 | $3,691 | — | — | — | — |
| Interest expense | $618,640 | $47,577 | $299 | $48,822 | $69,404 | $235,581 | — | — | — | — |
| Income before taxes | −$27.0M | −$14.9M | −$18.2M | −$26.7M | −$33.9M | −$28.5M | −$16.7M | −$2.8M | −$29,628 | −$32,800 |
| Net income | −$26.2M | −$14.2M | −$17.9M | −$23.6M | −$35.3M | −$31.8M | −$22.6M | −$2.8M | −$29,628 | −$32,800 |
| EBITDA | −$25.8M | −$14.4M | −$15.7M | −$22.1M | −$29.8M | −$24.3M | −$16.5M | −$2.8M | −$29,628 | −$32,800 |
| EPS (diluted) | −$6.73 | −$15.32 | −$26.53 | −$29.20 | −$35.07 | −$169.34 | −$82.99 | −$27.75 | −$0.29 | — |
| Gross margin | — | — | — | — | — | — | — | 100.0% | — | — |
| Operating margin | — | — | — | — | — | — | — | −13,586.0% | — | — |
| Net margin | — | — | — | — | — | — | — | −13,586.0% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $125,108 | $125,670 | $131,359 | $143,724 | $143,801 | $129,298 | $112,803 | $120,814 | $136,784 | $119,604 | $125,594 | $144,945 |
| Gross profit | −$125,108 | −$125,670 | −$131,359 | −$143,724 | −$143,801 | −$129,298 | −$112,803 | −$120,814 | −$136,784 | −$119,604 | −$125,594 | −$144,945 |
| Research & development | $377,589 | $617,419 | $70,404 | $495,223 | $549,197 | $1.6M | $4.3M | $744,802 | $897,986 | $160,260 | $29,961 | $32,985 |
| Sales, general & admin | $1.8M | $2.2M | $2.2M | $4.0M | $4.2M | $1.6M | $1.7M | $3.2M | $2.4M | $2.0M | $1.8M | $2.7M |
| Total operating expenses | $2.1M | $2.7M | −$8.0M | $4.7M | $4.9M | $3.4M | $6.2M | $4.2M | $3.5M | $2.3M | $1.8M | $3.3M |
| Operating income | −$2.2M | −$2.9M | $8.0M | −$4.7M | −$4.9M | −$3.4M | −$6.2M | −$4.2M | −$3.5M | −$2.3M | −$1.8M | −$3.3M |
| Interest income | — | — | $22,285 | $100,420 | $90,733 | $67,216 | $132,075 | $163,868 | $104,424 | $172,524 | $153,791 | $174,068 |
| Interest expense | $233,081 | $44,557 | $73,766 | $105,075 | $235,573 | $350,616 | $16,435 | $10,371 | $8,357 | $12,414 | $12 | — |
| Income before taxes | −$3.0M | −$13.6M | −$3.7M | −$4.7M | −$9.8M | −$8.7M | −$5.5M | −$4.0M | −$3.4M | −$2.1M | −$1.7M | −$1.1M |
| Net income | −$3.2M | −$13.4M | −$3.0M | −$5.3M | −$9.3M | −$8.6M | −$5.4M | −$3.8M | −$3.1M | −$1.9M | −$1.3M | −$1.1M |
| EBITDA | −$2.1M | −$13.4M | −$3.6M | −$4.5M | −$9.4M | −$8.3M | −$5.3M | −$3.9M | −$3.2M | −$2.0M | −$1.5M | −$2.7M |
| EPS (diluted) | −$0.47 | −$4.17 | — | −$1.77 | −$3.06 | −$2.33 | −$2.70 | −$4.17 | −$5.20 | −$3.25 | −$9.75 | −$0.03 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in QNTM's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
QNTM financial results
Quantum BioPharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $26.2 million. Diluted earnings per share came to −$6.73.
See the QNTM stock overview for the latest quote and news, or the QNTM chart for price history and technical indicators.
QNTM income statement FAQ
Does Quantum BioPharma have revenue?
Quantum BioPharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Quantum BioPharma profitable?
No. Quantum BioPharma reported a net loss of $26.2 million in fiscal 2025.
How much does Quantum BioPharma spend on research and development?
Quantum BioPharma spent $2.8 million on research and development in fiscal 2025.
What are Quantum BioPharma's earnings per share?
Quantum BioPharma earned $-6.73 per diluted share in fiscal 2025, compared with $-15.32 a year earlier.
When will Quantum BioPharma report its next earnings?
Quantum BioPharma is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Quantum BioPharma's fiscal year end?
Quantum BioPharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.